Name:
Lyoton 1000 gel gel for nar.prim. 1000 IU/g in 50g tubes No. 1
Description:
Gel for external use, colorless or with a slightly yellowish tint, almost transparent, viscous consistency. The main active ingredient Heparin sodium Release form Gel for external use is colorless or with a slightly yellowish tinge, almost transparent, viscous consistency. 100 g sodium heparin 100,000 IU Excipients: methyl parahydroxybenzoate – 0.12 g, propyl parahydroxybenzoate – 0.03 g, carbomer 940 – 1.25 g, ethyl alcohol 96% (ethanol) – 30 ml, neroli oil – 0.05 g, lavender oil – 0.05 g, triethanolamine (trolamine) – 0.85 g, purified water – up to 100 g. 50 g – aluminum tubes (1) – packs of cardboard. Use with caution in patients suffering from polyvalent allergies (including bronchial asthma), with arterial hypertension, dental procedures, diabetes mellitus, endocarditis, pericarditis, in the presence of an intrauterine contraceptive, with active tuberculosis, radiation therapy, liver failure, chronic renal failure, in elderly patients (over 60 years, especially women). The intramuscular injection of heparin is not recommended due to the possibility of developing a hematoma, as well as the intramuscular injection of other drugs during treatment with heparin. Use with caution externally for bleeding and conditions of increased bleeding, thrombocytopenia. During treatment with heparin, monitoring of blood coagulation parameters is necessary. For dilution of heparin, only physiological saline is used. With the development of severe thrombocytopenia (a decrease in the number of platelets by 2 times from the original number or below 100,000 / µl), it is necessary to urgently stop the use of heparin. The risk of bleeding can be minimized with careful evaluation of contraindications, regular laboratory monitoring of blood clotting, and adequate dosing. Pharmacological action Direct acting anticoagulant, belongs to the group of medium molecular weight heparins. In blood plasma, it activates antithrombin III, accelerating its anticoagulant effect. Violates the transition of prothrombin to thrombin, inhibits the activity of thrombin and activated factor X, to some extent reduces platelet aggregation. For unfractionated standard heparin, the ratio of antiplatelet activity (antifactor Xa) and anticoagulant activity (APTT) is 1:1. Increases renal blood flow; increases the resistance of cerebral vessels, reduces the activity of cerebral hyaluronidase, activates lipoprotein lipase and has a hypolipidemic effect. Reduces the activity of surfactant in the lungs, suppresses excessive synthesis of aldosterone in the adrenal cortex, binds adrenaline, modulates the ovarian response to hormonal stimuli, enhances the activity of parathyroid hormone. As a result of interaction with enzymes, it can increase the activity of brain tyrosine hydroxylase, pepsinogen, DNA polymerase and reduce the activity of myosin ATPase, pyruvate kinase, RNA polymerase, pepsin. There is evidence of immunosuppressive activity in heparin. In patients with coronary artery disease (in combination with ASA) reduces the risk of acute coronary artery thrombosis, myocardial infarction and sudden death. Reduces the frequency of recurrent heart attacks and mortality in patients with myocardial infarction. In high doses, it is effective for pulmonary embolism and venous thrombosis, in small doses it is effective for the prevention of venous thromboembolism, incl. after surgical operations. With intravenous administration, blood coagulation slows down almost immediately, with intramuscular injection – after 15-30 minutes, with s / c – after 20-60 minutes, after inhalation, the maximum effect is after a day; the duration of the anticoagulant action, respectively, is 4-5, 6, 8 hours and 1-2 weeks, the therapeutic effect – prevention of thrombosis – lasts much longer. Deficiency of antithrombin III in plasma or at the site of thrombosis may reduce the antithrombotic effect of heparin. When applied externally, it has a local antithrombotic, antiexudative, moderate anti-inflammatory effect. Blocks the formation of thrombin, inhibits the activity of hyaluronidase, activates the fibrinolytic properties of the blood. Penetrating through the skin, heparin reduces the inflammatory process and has an antithrombotic effect, improves microcirculation and activates tissue metabolism, thereby accelerating the processes of resorption of hematomas and blood clots and reducing tissue swelling. Pharmacokinetics After s / c administration, Cmax of the active substance in plasma is observed after 3-4 hours. Heparin poorly crosses the placenta due to its large molecular weight. Not excreted in breast milk. T1 / 2 from plasma is 30-60 minutes. Indications for use Prevention and therapy: deep vein thrombosis, pulmonary embolism (including in peripheral vein diseases), coronary artery thrombosis, thrombophlebitis, unstable angina, acute myocardial infarction, atrial fibrillation (including accompanied by embolism), DIC, prevention and therapy of microthrombosis and microcirculation disorders, renal vein thrombosis, hemolytic uremic syndrome, mitral heart disease (thrombosis prevention), bacterial endocarditis, glomerulonephritis, lupus nephritis. Prevention of blood coagulation during operations using extracorporeal methods of blood circulation, during hemodialysis, hemosorption, peritoneal dialysis, cytopheresis, forced diuresis, when washing venous catheters. Preparation of non-clotting blood samples for laboratory purposes and blood transfusion. Dosage and administration Individual, depending on the dosage form used, indications, clinical situation and patient’s age. Use during pregnancy and lactation Use during pregnancy is possible only under strict indications, under close medical supervision. May be used during lactation (breastfeeding) according to indications. Precautions Use with caution in patients with chronic renal failure. Use with caution in elderly patients (over 60 years, especially in women). Interaction with other drugs The anticoagulant effect of heparin is enhanced with the simultaneous use of anticoagulants, antiplatelet agents and NSAIDs. Ergot alkaloids, thyroxine, tetracycline, antihistamines, and nicotine reduce the effect of heparin. Bleeding, diseases accompanied by impaired blood coagulation, suspected intracranial hemorrhage, cerebral aneurysm, hemorrhagic stroke, dissecting aortic aneurysm, antiphospholipid syndrome, malignant arterial hypertension, subacute bacterial endocarditis, erosive and ulcerative lesions of the gastrointestinal tract, severe lesions of the liver parenchyma, cirrhosis liver with varicose veins of the esophagus, malignant neoplasms in the liver, shock conditions, recent surgical interventions on the eyes, brain, prostate gland, liver and biliary tract, condition after spinal cord puncture, menstruation, threatened miscarriage, childbirth (incl. recent), hypersensitivity to heparin. Do not apply to open wounds, mucous membranes, do not use in ulcerative necrotic processes. Composition heparin sodium 100,000 IU Excipients: methyl parahydroxybenzoate – 0.12 g, propyl parahydroxybenzoate – 0.03 g, carbomer 940 – 1.25 g, ethyl alcohol 96% (ethanol) – 30 ml, neroli oil – 0.05 g, lavender oil – 0.05 g, triethanolamine (trolamine ) – 0.85 g, purified water – up to 100 g. In case of overdose, the effect of heparin can be neutralized with a solution of protamine sulfate. Side effects On the part of the blood coagulation system: possible bleeding of the gastrointestinal tract and urinary tract, bleeding at the injection site, in areas subjected to pressure, from surgical wounds, as well as hemorrhages in other organs, hematuria, thrombocytopenia. From the digestive system: nausea, loss of appetite, vomiting, diarrhea, increased activity of hepatic transaminases. Allergic reactions: skin flushing, drug fever, urticaria, rhinitis, pruritus and feeling of heat in the soles, bronchospasm, collapse, anaphylactic shock. From the blood coagulation system: thrombocytopenia (may be severe, even fatal) with subsequent development of skin necrosis, arterial thrombosis, accompanied by the development of gangrene, myocardial infarction, stroke. From the musculoskeletal system: with prolonged use – osteoporosis, spontaneous fractures, soft tissue calcification. Local reactions: irritation, pain, hyperemia, hematoma and ulceration at the injection site. Others: transient alopecia, hypoaldosteronism. Storage conditions At a temperature not higher than 25 ° C. Keep out of the reach of children! Buy Lyoton 1000 gel gel 1000 IU/g 50g No. 1
Lioton 1000 gel gel 1000 IU/g 50g №1
$28.00
INN | HEPARIN |
---|---|
The code | 171 |
Barcode | 4 013 054 003 923 |
Dosage | 1000IU/g 50g |
Active substance | Heparin |
Manufacturer | A.Menarini Manufactch. Logistics and Serv. s.r.l., Italy for A.Menar Industr.Pharmac. Riunite (Menar.gr), Italy |
Importer | IOOO Interfarmaks 223028 Minsk region, Minsk district, Zhdanovichsky s / s, ag. Zhdanovichi, st. Star, 19a-5, room. 5-2 |
Be the first to review “Lioton 1000 gel gel 1000 IU/g 50g №1” Cancel reply
Related products
Treatment and prevention of hemorrhoids and varicose veins
Treatment and prevention of hemorrhoids and varicose veins
Treatment and prevention of hemorrhoids and varicose veins
Treatment and prevention of hemorrhoids and varicose veins
Treatment and prevention of hemorrhoids and varicose veins
Treatment and prevention of hemorrhoids and varicose veins
Treatment and prevention of hemorrhoids and varicose veins
Treatment and prevention of hemorrhoids and varicose veins
Reviews
There are no reviews yet.